Welcome and Introduction to Vi3C

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Feb

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

Oncolytic Virus Triggers Immune System Against Glioblastoma Cells

Adjuvant Durvalumab in Resected Early-Stage NSCLC

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products

Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk